3-pentyloctan-1-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-pentyloctan-1-ol
• 化学式: C₁₃H₂₈O
• 分子量: 200.365
• InChiKey: ZRIVEULBLVCCSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  14
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-pentyloctan-1-ol 在 potassium tert-butylate 、 silica gel 、 pyridinium chlorochromate 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 2.75h， 生成 6-allylundecane
  参考文献：
  名称：

  WO2021055833A5

  摘要：

  公开号：

  WO2021055833A5
• 作为产物：
  描述：

  二正戊基酮 在 lithium aluminium tetrahydride 、 10 wt% Pd(OH)2 on carbon 、 水 、 氢气 、 sodium hydride 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 为溶剂， 20.0 ℃ 、1.38 MPa 条件下， 反应 62.5h， 生成 3-pentyloctan-1-ol
  参考文献：
  名称：

  [EN] LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING PHENYLALANINE HYDROXYLASE AND USES THEREOF
  [FR] NANOPARTICULES LIPIDIQUES CONTENANT DES POLYNUCLÉOTIDES CODANT POUR LA PHÉNYLALANINE HYDROXYLASE ET LEURS UTILISATIONS

  摘要：

  本文涉及离子化氨基脂质基纳米粒子，用于传递编码苯丙氨酸羟化酶的mRNA。发明的脂质纳米粒子/mRNA疗法可以增加和/或恢复受试者中苯丙氨酸羟化酶表达和/或活性的不足水平，适用于苯丙酮尿症的治疗。

  公开号：

  WO2022204390A1

文献信息

• [EN] BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS<br/>[FR] LIPIDES BIODÉGRADABLES POUR L'ADMINISTRATION D'AGENTS ACTIFS
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2013086354A1

  公开（公告）日：2013-06-13

  The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种阳离子脂质，其中在阳离子脂质的脂质部分（例如，疏水链）中具有一个或多个可生物降解的基团。这些阳离子脂质可以掺入脂质粒子中，用于递送一种活性剂，例如核酸。本发明还涉及包含中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选的甾醇的脂质粒子。脂质粒子还可以进一步包括治疗剂，例如核酸。
• Substituted melatonin derivatives, process for their preparation, and methods of use
  申请人：Tao Chunlin

  公开号：US20070191463A1

  公开（公告）日：2007-08-16

  The invention provides 2 aryl substituted derivatives of melatonin. The invention further provides pharmaceutical compositions comprising such derivatives, methods for preparing such derivatives, and methods of using such derivatives to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient, and to treat conditions affected by melatonin activity in a patient.

  这项发明提供了2种芳基取代的褪黑激素衍生物。该发明还提供了包括这些衍生物的药物组合物，制备这些衍生物的方法，以及利用这些衍生物在患者中诱导全身麻醉、镇静和/或催眠或睡眠效果，并治疗受褪黑激素活性影响的患者病况的方法。
• Diarylalkanes as potent inhibitors of binuclear enzymes
  申请人：Jia Qi

  公开号：US20050267047A1

  公开（公告）日：2005-12-01

  The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzyme function. The present invention further includes a method for preventing and treating melanin overproduction and diseases and conditions of the skin related thereto. The method for preventing and treating diseases and conditions related to binuclear enzyme function and melanin overproduction is comprised of administering to a host in need thereof an effective amount of a composition comprising one or more diarylalkanes and/or diarylalkanols synthesized and/or isolated from one or more plants together with a pharmaceutically acceptable carrier.

  本发明实施了一种策略，将酶抑制测定与化学去重复过程相结合，以识别活性植物提取物和特定化合物——二芳基烷烃和/或二芳基醇，这些化合物特异性地抑制双核酶功能。本发明包括由一种或多种二芳基烷烃和/或二芳基醇组成的物质组合物，其抑制双核酶的活性，特别是酪氨酸酶，并防止黑色素过度产生。本发明还提供了一种抑制双核酶活性的方法，特别是酪氨酸酶，以及一种预防和治疗与双核酶功能相关的疾病和病况的方法。本发明还包括一种预防和治疗黑色素过度产生以及与之相关的皮肤疾病和病况的方法。预防和治疗与双核酶功能和黑色素过度产生相关的疾病和病况的方法包括向需要的宿主施用由一种或多种植物合成和/或分离的一种或多种二芳基烷烃和/或二芳基醇组成的组合物的有效量，以及药用载体。
• Cationic Lipid
  申请人：EISAI R&D MANAGEMENT CO., LTD.

  公开号：US20200308111A1

  公开（公告）日：2020-10-01

  The present invention provides a cationic lipid which is able to be used for nucleic acid delivery to the cytoplasm. A cationic lipid according to the present invention is, for example, a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein L 1 and L 2 independently represent an alkylene group having 3 to 10 carbon atoms; R 1 and R 2 independently represent an alkyl group having 4 to 24 carbon atoms or an alkenyl group having 4 to 24 carbon atoms; R 3 represents an alkyl group having 1 to 3 carbon atoms; and X 1 represents a single bond or CO—O—.

  本发明提供了一种阳离子脂质，可用于将核酸传递至细胞质。根据本发明的一种阳离子脂质，例如，是由式（1）表示的化合物或其药学上可接受的盐，其中L1和L2分别表示具有3至10个碳原子的烷基基团；R1和R2分别表示具有4至24个碳原子的烷基基团或具有4至24个碳原子的烯基基团；R3表示具有1至3个碳原子的烷基基团；X1表示单键或CO—O—。
• [EN] RIBOSE CATIONIC LIPIDS<br/>[FR] LIPIDES CATIONIQUES DE RIBOSE
  申请人：TRANSLATE BIO INC

  公开号：WO2019222424A1

  公开（公告）日：2019-11-21

  Disclosed are cationic lipids which are compounds of Formula (I'). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

  揭示了一种符合式（I'）的阳离子脂质化合物。本文提供的阳离子脂质可以用于传递和表达mRNA和编码的蛋白质，例如作为脂质体传递载体的组成部分，因此可以用于治疗各种疾病、疾病和症状，如与一种或多种蛋白质缺乏有关的情况。